BioLineRx Ltd.
BLRX
$2.75
-$0.32-10.42%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 56.54% | 83.22% | -914.05% | 836.64% | 77.05% |
| Total Depreciation and Amortization | -101.07% | -85.83% | -63.03% | -81.61% | 174.96% |
| Total Amortization of Deferred Charges | -18.00% | -- | -100.00% | -- | 69.49% |
| Total Other Non-Cash Items | 71.60% | 23.99% | 129.98% | -128.02% | -299.02% |
| Change in Net Operating Assets | 119.27% | 94.85% | 125.96% | 95.24% | -102.79% |
| Cash from Operations | 62.83% | 78.56% | 98.44% | 81.64% | -272.51% |
| Capital Expenditure | -516.67% | -- | -- | -- | 137.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -102.80% | -63.79% | 56.89% | -148.91% | 154.72% |
| Cash from Investing | -103.02% | -63.90% | 57.15% | -149.00% | 154.70% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 89.66% | -21.00% | -38.06% | -39.49% | -1,302.43% |
| Issuance of Common Stock | -100.00% | -- | -48.66% | -- | -12.77% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -12.89% | 24.79% | -93.29% | 1,157.05% | -109.45% |
| Foreign Exchange rate Adjustments | -22.84% | -8.64% | 258.82% | -260.78% | -15.63% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -391.50% | 192.12% | -150.84% | -180.69% | 146.08% |